Samuel Smith, PhD, of Queen Mary University of London, discusses study findings on menopausal symptoms as predictors of long‐term adherence in an International breast cancer intervention study (Abstract S5-03).
Ruth O’Regan, MD, of the University of Wisconsin, and Ann H. Partridge, MD, of the Dana-Farber Cancer Institute, discuss study findings on the prognostic associations of TILs in metastatic HER2-positive breast cancer (Abstract S1-04).
Virginia G. Kaklamani, MD, DSc, of The University of Texas Health Science Center, discusses new directions in prevention, early detection, and treatment of early-stage breast cancer, using genomic tests and targeted therapies.
Lisa A. Carey, MD, of the University of North Carolina, discusses a session she moderated on key data presented at SABCS, and gives her expert views on putting the research data into clinical practice.
Dawn Hershman, MD, of the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, reviews findings on survivorship care plans, interventions to reduce chemotherapy-induced peripheral neuropathy, and the cardiac effects of aromatase inhibitors (Poster Discussion 4).
Peter Bach, MD, of Memorial Sloan Kettering Cancer Center, summarizes his plenary lecture on drug costs and their effect on the affordability of cancer care worldwide (Plenary Lecture 3).
